NEW YORK, Jan 23 – Phase-1 Molecular Toxicology, a privately held Santa Fe, N.M.–based toxicogenomics company, said Tuesday it has signed an agreement to sell Axon Instruments’ GenePx 4000B microarray scanner along with its toxicogenomic and toxicoproteomic microarrays and software.

The companies will offer the scanner, arrays, and software as a package deal, according to Phase-1 CEO Spencer Farr, who declined to specify how the companies will share revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.